mesenchymal stem cell complete media  (ATCC)

Journal: bioRxiv

Article Title: Plasma-Enabled Multiscale Coupling of Architecture and Biointerfaces Drives Osteogenesis in 3D-Printed Gyroid Scaffolds

doi: 10.64898/2026.04.16.718992

Figure Lengend Snippet: Fabrication and surface characterization of silver nanoparticle (AgNP)-functionalized PLA scaffolds. A) Schematic illustration of the scaffold fabrication and surface modification workflow: hexagonal honeycomb G-code was used to 3D-print PLA scaffolds, which were subsequently dip-coated in AgNO₃ solution, with or without prior incubation in polydopamine hydrochloride (PDA), followed by Plasma Electroless Reduction (PER) under H₂ gas to yield PLA+AgNP and PLA+PDA+AgNP constructs, respectively. B) Representative scanning electron microscopy (SEM) images of PLA+AgNP (top row) and PLA+PDA+AgNP (bottom row) scaffolds fabricated across a range of AgNO₃ concentrations (0–25 mM), with corresponding optical images of the scaffold surface shown as insets. Scale bars = 5 µm. C) SEM micrographs of L929 fibroblasts (top row) and human mesenchymal stem cells (hMSCs, bottom row) adhered to unmodified PLA HC, PLA HC+AgNP (0.7 mM AgNO₃), and PLA HC+PDA+AgNP (0.7 mM AgNO₃) scaffolds. Black arrows indicate representative cell–scaffold interactions. Scale bars = 15 µm.

Article Snippet: The cells were incubated in mesenchymal stem cell complete media (Basal media: ATCC, USA: Cat no: PCS-500-030 and growth kit: ATCC, USA: Cat no: PCS-500-041) for five days.

Techniques: Modification, Incubation, Clinical Proteomics, Construct, Electron Microscopy

Journal: PLOS ONE

Article Title: Recovery after human bone marrow mesenchymal stem cells (hBM-MSCs)-derived extracellular vesicles (EVs) treatment in post-MCAO rats requires repeated handling

doi: 10.1371/journal.pone.0312298

Figure Lengend Snippet: (a–c) Characterization and quantification of human-bone marrow mesenchymal stem cell (hBM-MSC)-derived extracellular vesicles (EVs). (a) Nanosight Tracking analyses (NTA) showing the size distribution pattern of EVs. (b) Western blots of hBM-MSCs marker (GM130) and EVs markers (ALIX, CD9, CD81). “Wash” lane represents the negative control. Each image comes from different blots. (c) Representative image of EVs using transmission electron microscopy (TEM). Scale bar 100 nm. (d–f) In vivo tracking of ExoGlow-labeled EVs demonstrated that EVs reach the brain and accumulate near the stroke injury 6 hours after administration at 2 dps. (d) Timeline of intranasal single dose treatment of ExoGlow-labeled EVs (~2.4 x 10 9 EVs in 200 μl), starting 2 dps and collecting the tissue 6 hours after. (e) Representative coronal section after a single intranasal administration of ExoGlow-labeled EVs (~2.4 x 10 9 EVs in 200 μl) at 2 dps. Hoechst indicates cell nuclei. Scale bars 4 mm and 100 μm. (f) Quantification of the average size of ExoGlow+ particles in the ipsilateral and contralateral hemispheres. Data was analyzed using a paired t-test (*p<0.05). Bars show mean +/− SD. Each symbol represents the average size of ExoGlow+ particles from all ROIs in each hemisphere (5 ROIs/hemisphere in each rat) of a single rat ( n = 4 ).

Article Snippet: Cells were maintained and expanded with human (bone marrow-derived) mesenchymal stem cell complete media with serum (Celprogen, #M36094-21S) at 37°C in a 5% CO 2 atmosphere.

Techniques: Derivative Assay, Western Blot, Marker, Negative Control, Transmission Assay, Electron Microscopy, In Vivo, Labeling